Becton, Dickinson and Company (NYSE:BDX) Shares Bought by WealthPLAN Partners LLC

WealthPLAN Partners LLC increased its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 1,927.1% in the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 5,088 shares of the medical instruments supplier’s stock after buying an additional 4,837 shares during the period. WealthPLAN Partners LLC’s holdings in Becton, Dickinson and were worth $993,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. BlackRock Inc. boosted its position in Becton, Dickinson and by 2,427.8% during the first quarter. BlackRock Inc. now owns 16,542,028 shares of the medical instruments supplier’s stock worth $3,034,470,000 after purchasing an additional 15,887,611 shares during the period. Vanguard Group Inc. boosted its position in Becton, Dickinson and by 8.5% during the second quarter. Vanguard Group Inc. now owns 17,255,948 shares of the medical instruments supplier’s stock worth $3,366,809,000 after purchasing an additional 1,353,780 shares during the period. Los Angeles Capital Management & Equity Research Inc. boosted its position in Becton, Dickinson and by 49,944.3% during the second quarter. Los Angeles Capital Management & Equity Research Inc. now owns 863,264 shares of the medical instruments supplier’s stock worth $168,431,000 after purchasing an additional 861,539 shares during the period. Findlay Park Partners LLP boosted its position in Becton, Dickinson and by 85.1% during the second quarter. Findlay Park Partners LLP now owns 1,725,000 shares of the medical instruments supplier’s stock worth $336,565,000 after purchasing an additional 792,942 shares during the period. Finally, Principal Financial Group Inc. boosted its position in Becton, Dickinson and by 185.3% during the second quarter. Principal Financial Group Inc. now owns 909,235 shares of the medical instruments supplier’s stock worth $177,401,000 after purchasing an additional 590,494 shares during the period. Institutional investors and hedge funds own 86.83% of the company’s stock.

A number of brokerages have weighed in on BDX. Wells Fargo & Company reiterated a “positive” rating and set a $235.00 target price (up previously from $225.00) on shares of Becton, Dickinson and in a research report on Tuesday. They noted that the move was a valuation call. Royal Bank Of Canada restated a “hold” rating and issued a $210.00 price objective on shares of Becton, Dickinson and in a research report on Wednesday. Zacks Investment Research upgraded shares of Becton, Dickinson and from a “sell” rating to a “hold” rating in a research report on Friday, October 20th. Bank of America Corporation restated a “buy” rating and issued a $225.00 price objective (up from $200.00) on shares of Becton, Dickinson and in a research report on Friday, July 21st. Finally, Piper Jaffray Companies restated a “buy” rating and issued a $213.00 price objective on shares of Becton, Dickinson and in a research report on Tuesday, September 12th. Five investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $205.14.

Becton, Dickinson and Company (NYSE BDX) opened at 209.84 on Friday. The firm’s 50 day moving average is $199.26 and its 200 day moving average is $194.48. The stock has a market capitalization of $47.75 billion, a P/E ratio of 60.77 and a beta of 1.05. Becton, Dickinson and Company has a 1-year low of $161.29 and a 1-year high of $214.72.

Becton, Dickinson and (NYSE:BDX) last issued its quarterly earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.44 by $0.02. The firm had revenue of $3.04 billion for the quarter, compared to analyst estimates of $3.06 billion. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. The business’s revenue was down 5.1% on a year-over-year basis. During the same period in the previous year, the company posted $2.35 earnings per share. On average, equities research analysts anticipate that Becton, Dickinson and Company will post $9.46 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This story was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this story can be read at https://www.dispatchtribunal.com/2017/10/27/wealthplan-partners-llc-has-993000-position-in-becton-dickinson-and-company-bdx.html.

In other Becton, Dickinson and news, insider Thomas E. Polen, Jr. sold 5,971 shares of the business’s stock in a transaction on Wednesday, August 9th. The stock was sold at an average price of $197.41, for a total transaction of $1,178,735.11. Following the transaction, the insider now owns 12,861 shares of the company’s stock, valued at $2,538,890.01. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Ellen R. Strahlman sold 9,283 shares of the business’s stock in a transaction on Thursday, August 10th. The stock was sold at an average price of $198.21, for a total value of $1,839,983.43. Following the transaction, the insider now directly owns 26,638 shares in the company, valued at approximately $5,279,917.98. The disclosure for this sale can be found here. Insiders sold 75,904 shares of company stock worth $15,242,688 over the last ninety days. Corporate insiders own 1.40% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply